Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Financing Activities (2022 - 2025)

BioXcel Therapeutics has reported Cash from Financing Activities over the past 4 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $5.6 million for Q4 2025, up 32.06% from a year ago — trailing twelve months through Dec 2025 was $56.5 million (up 54.17% YoY), and the annual figure for FY2025 was $56.5 million, up 54.17%.
  • Cash from Financing Activities for Q4 2025 was $5.6 million at BioXcel Therapeutics, down from $37.5 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for BTAI hit a ceiling of $37.5 million in Q3 2025 and a floor of $50000.0 in Q4 2022.
  • Median Cash from Financing Activities over the past 4 years was $5.3 million (2024), compared with a mean of $11.5 million.
  • Peak annual rise in Cash from Financing Activities hit 8166.96% in 2025, while the deepest fall reached 97.42% in 2025.
  • BioXcel Therapeutics' Cash from Financing Activities stood at $50000.0 in 2022, then soared by 4146.0% to $2.1 million in 2023, then soared by 101.41% to $4.3 million in 2024, then skyrocketed by 32.06% to $5.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were $5.6 million (Q4 2025), $37.5 million (Q3 2025), and $137000.0 (Q2 2025) per Business Quant data.